Previous Close | 42.25 |
Open | 42.50 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 40.75 - 42.50 |
52 Week Range | 39.50 - 96.25 |
Volume | |
Avg. Volume | 9,297,775 |
Market Cap | 32.799B |
Beta (5Y Monthly) | 0.83 |
PE Ratio (TTM) | 14.24 |
EPS (TTM) | 2.86 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | 2.00 (4.55%) |
Ex-Dividend Date | Mar 11, 2022 |
1y Target Est | 62.09 |
If you want to know who really controls Gossamer Bio, Inc. ( NASDAQ:GOSS ), then you'll have to look at the makeup of...
SAN DIEGO, October 11, 2021--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the addition of two CNS-penetrant Bruton’s tyrosine kinase (BTK) inhibitors to its product candidate pipeline.
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...